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Abstract
Following attachment to primary receptor heparan sulfate proteoglycans (HSPG), human papillomavirus type 16 (HPV16)
particles undergo conformational changes affecting the major and minor capsid proteins, L1 and L2, respectively. This
results in exposure of the L2 N-terminus, transfer to uptake receptors, and infectious internalization. Here, we report that
target cell cyclophilins, peptidyl-prolyl cis/trans isomerases, are required for efficient HPV16 infection. Cell surface
cyclophilin B (CyPB) facilitates conformational changes in capsid proteins, resulting in exposure of the L2 N-terminus.
Inhibition of CyPB blocked HPV16 infection by inducing noninfectious internalization. Mutation of a putative CyP binding
site present in HPV16 L2 yielded exposed L2 N-terminus in the absence of active CyP and bypassed the need for cell surface
CyPB. However, this mutant was still sensitive to CyP inhibition and required CyP for completion of infection, probably after
internalization. Taken together, these data suggest that CyP is required during two distinct steps of HPV16 infection.
Identification of cell surface CyPB will facilitate the study of the complex events preceding internalization and adds a
putative drug target for prevention of HPV–induced diseases.
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Introduction
Cyclophilins (CyP) comprise a family of peptidyl-prolyl cis/trans
isomerases, which are evolutionarily conserved and ubiquitously
expressed [1,2]. CyP facilitate folding of nascent proteins and
through this have been implicated in RNA splicing, stress
responses, gene expression, cell signaling, mitochondrial function,
and regulation of kinase activity [3]. The 16 human family
members differ mainly by terminal extensions, which are probably
responsible for subcellular localization and protein-protein inter-
actions, and by tissue specific expression. CyP were initially
identified as high affinity binding proteins for cyclosporin A (CsA),
an immunosuppressive agent [4]. CsA blocks the enzymatic
acitivity of CyP. Cyclophilin A and B (CyPA and CyPB) are the
most abundant among the family, where CyPA mainly localizes to
the cytoplasm and CyPB, which encodes a signal peptide, is
associated with the endoplasmic reticulum (ER). CyPB can be
secreted and is detected on the cell surface, where it colocalizes
with heparan sulfate proteoglycans (HSPGs) like syndecan-1 [5].
Recent reports suggest that CyPB preferentially bind HSPG
molecules that carry a 3-O-sulfated N-unsubstituted glucosamino-
glycan residue in the heparan chain [6]. 3-O-sulfation is the least
abundant modification of heparan sulfate and thus only few HSPG
molecules on the cell surface are associated with CyPB. The core
protein required for triggering biological function of cell surface
CyPB is most likely syndecan-1 [5].
Several viruses exploit CyP for life cycle completion. The capsid
protein of human immunodeficiency virus type 1 (HIV-1) harbors
a CyPA binding site resulting in the incorporation of this
chaperone into the virion [7]. In addition, target cell CyPA is
required for efficient infection of human cells [8,9]. Inhibition of
CyPA prevents the transport of reverse transcribed viral genome
to the nucleus without interfering with reverse transcription [10].
A number of observations were interpreted as CyPA preventing
the interaction of the viral capsid protein with restriction factors
rather than it promoting viral uncoating. In some nonpermissive
cells, CyPA activity is required for binding of the restriction factor
TRIM5 to the capsid protein (for review see [7]). Hepatitis C virus
(HCV) is another example requiring CyPB activity for efficient
replication. It interacts with the viral polymerase NS5B thus
promoting RNA binding [11]. Furthermore, mouse cytomegalo-
virus (MCMV) infection of neural stem/progenitor cells is
facilitated by CyPA by an unknown mechanism [12].
Here we demonstrate that CyPB activity facilitates infection of
human papillomavirus type 16 (HPV16) and HPV18. HPV are
non-enveloped epitheliotropic DNA viruses with a circular,
chromatinized, double stranded DNA genome of approximately
8000 bp. They induce benign lesions of the skin and mucosa that
in some instances progress to malignancies. HPV induced
malignancies, including cervical carcinoma, contribute to more
than 7% of all cancers in women worldwide. The viral capsid is
composed of 360 copies of the major capsid protein, L1, and up to
PLoS Pathogens | www.plospathogens.org 1 July 2009 | Volume 5 | Issue 7 | e100052472 copies of the minor capsid protein, L2 [13–15]. L1 protein,
which is organized in 72 pentamers, called capsomeres, mediates
the primary attachment of viral particles to the cell surface [16–18]
and/or extracellular matrix (ECM) of susceptible cells [19], most
probably via HSPG [20]. The need for HS can be bypassed by
treatment of immature HPV16 pseudovirions with furin con-
vertase [21]. The primary attachment is mediated by surface-
exposed lysine residues located at the rim of capsomeres [22].
HPV33 binding to the cell surface requires O-sulfation of HS,
whereas both N- and O-sulfation are needed for HSPG to function
as an initiator of the infectious entry pathway [23]. These data
suggested that secondary HSPG interactions may play a role in
infection, which was recently supported by the use of the HS
binding drug DSTP-27 [18]. Virus attachment triggers confor-
mational changes in both capsid proteins [23–25], which seem to
be required for transfer to putative secondary receptors and
infectious internalization [18]. Conformational changes result in
the exposure of the N-terminus of L2 protein, which contains a
highly cross-reactive neutralizing epitope, and subsequent cleavage
of 12 N-terminal amino acids catalyzed by furin convertase
[24,26]. Data presented below suggest that cell surface CyPB
facilitates exposure of the L2 N-terminus, which is required for
infectious internalization.
Results
Effect of CyP inhibition on HPV16 and HPV18 infection
We used a well established pseudovirus system for our studies,
which relies on the expression of codon-modified forms of L1 and
L2 in human embryonic kidney 293TT cells harboring a high
copy number packaging plasmid [27]. We packaged a green
fluorescent protein (GFP)–based marker plasmid that has been
successfully used before to study early events of HPV infection
[28–31]. We observed that CsA efficiently blocked HPV16
infection of 293TT cells with an inhibitory concentration 50
(IC50) of approximately 2 mM (Figure 1A). Similar results were
obtained for HaCaT, which is currently the most commonly used
keratinocytes-derived cell line for analysis of HPV infection, and
HPV-harboring HeLa (Figure 1B). CsA has been shown to block
activity of calcineurin and CyP as well as P-glycoproteins, also
known as ABC transporters. We used more specific inhibitors to
narrow down the cellular target responsible for the observed
inhibition. Neither INCA-6 nor the cell permeable R-VIVIT
peptide and FK506, inhibitors of the interaction between
calcineurin and nuclear factor of activated T cells (NFAT),
blocked infection (Figure 1C). Similarly, Virapamil and nifedipine,
specific inhibitors of P-glycoproteins, had no effect. In contrast,
NIM811, which blocks both P-glycoproteins and CyP, inhibited
HPV16 infection as efficiently as CsA. Identical results were
obtained for key inhibitor NIM811 in HaCaT cells (data not
shown). All inhibitors reduced cell growth of 293TT (Figure 1D),
HaCaT and HeLa (not shown) cells to a similar extent. Cell
growth inhibition of these inhibitors is well established. Taken
together, these results strongly suggest that CyP facilitate HPV16
and HPV18 infection.
siRNA mediated knock down of CyP
In order to determine, which CyP family member may be
involved and to confirm our findings, we used an siRNA approach
to knock down individual CyP. First, we used an siRNA, si-
CyP[broad], which has been shown to target several members of
the CyP family including CyPA, CyPB, CyPE, and CyPH [11].
293TT cells were transfected with si-CyP[broad] 48 prior to
infection with HPV16. Western blot confirmed the significant
reduction of steady state CyPA and CyPB protein levels (Figure 2B)
and infection was reduced to 11% (p,0.01) compared to cells
transfected with a control siRNA (Figure 2A). Individual knock
down of CyPA and CyPB with specific validated siRNAs [11] also
reduced infection to 59% (p,0.05) and 35% (p,0.01), respec-
tively. Specificity of the siRNA knock down for their target was
confirmed by Western blot (Figure 2B). The data indicated that
both CyP may play a role in HPV16 infection. Compared to
CyPA, knockdown of CyPB consistently resulted in stronger
inhibition (p,0.05). Similar results were obtained for HaCaT
cells. However, due to reduced transfection efficiency of HaCaT
cells (70% vs. 95% for 293TT) the inhibitory effect was not as
pronounced (Figure 2C and 2D).
Internalization of viral capsids in presence of CyP
inhibitors
To identify the stage at which infection is blocked by CyP
inhibitors, we first measured internalization using immunofluores-
cence (IF). It was shown by several groups that most surface-
exposed conformational epitopes that are recognized by neutral-
izing monoclonal antibodies (NmAb) are destroyed following entry
and that L1 protein segregates from the L2/DNA complex in
acidic endocytic compartments [18,29,30]. During this process
reactivity of antibodies specific for hidden linear L1 epitopes is
gained [32]. We used NmAb H16.56E to determine if conforma-
tional epitopes are lost in the presence of NIM811. H16.56E
binding site includes but is not restricted to the N-terminal portion
of the FG loop (HPV16 L1 residues 260–270) [33]. We also used
mAb 33L1-7, which binds a linear epitope (residues 303–313) that
is neither accessible in capsomeres nor in intact particles [34,35]
and recognizes L1 protein late in HPV entry [32]. In untreated
cells at 18 h post infection (hpi) with HPV16 pseudovirus,
H16.56E reactivity was hardly detectable but perinuclear 33L1-7
staining was obvious indicative of particle internalization and
accessibility of the 33L1-7 epitope (Figure 3A). In contrast, we
observed a strongly increased perinuclear signal with H16.56E
when infection was performed in the presence of 10 mM NIM811.
The signal for 33L1-7 was greatly diminished under these
Author Summary
Human papillomaviruses (HPV), especially HPV types 16
and 18, are a major cause of cancer in women worldwide.
HPV16, like most genital HPV types, relies on heparan
sulfate proteoglycans (HSPGs) to attach to host cells and to
the extracellular matrix. Attachment is mediated by
surface-exposed basic residues of the major capsid protein,
L1. This triggers conformational changes affecting L1 and
the minor capsid protein, L2. However, it is not known
what interaction triggers these structural changes and if
any host cell protein is involved. Now we have identified a
host cell chaperone, Cyclophilin B (CyPB), as essential for
efficient HPV16 and HPV18 infection. CyPB, which is
present on the cell surface in association with specific
forms of O-sulfated HSPG as well as in the lumen of
intracellular membrane structures, is an energy-indepen-
dent enzyme, which catalyzes cis/trans isomerization of
peptidyl-prolyl bonds. We demonstrate that CyPB facili-
tates conformational changes resulting in exposure of the
L2 N-terminus, which is required for infectious entry. In
addition, we present some evidence suggesting that
members of the cyclophilin family are required for a
second, probably intracellular, step of HPV16 infection.
This is the first report implicating cell surface chaperones
as essential host factors for viral infection.
CyP and HPV Infection
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NIM811 was replaced by CsA (data not shown). We will use the
term ‘stabilized capsid phenotype’ to describe the increased
reactivity of internalized pseudovirions with H16.56E. These data
demonstrate that, first, viral particles are indeed internalized in the
presence of CyP inhibitor and, second, the conformational L1
epitope recognized by H16.56E is stabilized.
We again used siRNA knock down to identify the CyP family
member responsible for the stabilized capsid phenotype. For this,
HaCaT cells were transfected with unspecific control siRNA, si-
CyP[broad], si-CyPA or si-CyPB 48 h prior to infection with
HPV16 pseudovirus. Successful down regulation of CyPB was
confirmed by IF (Figure 3B). Down regulation of CyPA could not
be determined by IF because of lack of CyPA-specific antibody
reactivity in this assay. However, successful transfection was
monitored using FITC-labeled siRNA (not shown) and knock
down of CyPA was confirmed by Western blot. Cells with reduced
levels of CyPB following transfection with si-CyPB or si-
CyP[broad] displayed a stabilized capsid phenotype at 18 hpi,
whereas adjacent cells, which were not transfected as indicated by
strong staining for CyPB, showed much less reactivity with
H16.56E (Figure 3B). A stabilized capsid phenotype was not
detected in cells transfected with si-CyPA, even though basal level
of reactivity with H16.56E is evident. Taken together these data
suggest that blockage of CyPB activity may be responsible for the
stabilized capsid phenotype.
Effect of CyP inhibitors on L2 conformational changes
Previously we observed a stabilized capsid phenotype when
transfer to secondary receptors on the cell surface was blocked by
antibodies or drugs [18]. Furthermore, CyPB is found on the cell
surface where it is associated with HSPG [6,36]. Therefore, we
hypothesized that CyPB may facilitate the conformational shifts
reported for both capsid proteins upon interaction with cell surface
HSPG [23,25]. Currently, the only reliable test for these changes
measures the exposure of the L2 N-terminus using the L2-specific
NmAb RG-1. RG-1 binds to a peptide encompassing HPV16 L2
r e s i d u e s1 7t o3 6[ 3 7 ] .R G - 1r e a c t i v i t yw i t hL 2p r o t e i ni n c o r p o r a t e d
into virions requires cell attachment-induced exposure of the L2 N-
terminus and furin cleavage [24]. To test the role of CyP in
conformational shifts, HPV16 pseudovirus was bound to HaCaT
cells for 2 h at 4uC and was chased for 4 h at 37uCp r i o rt oc e l l
surface staining with RG-1 (a kind gift of R.B. Roden, John Hopkins
University) and K75 polyclonal VLP antisera. In control infection we
found strong RG-1 signal, which perfectly overlapped with cell-
associated L1-specific K75 binding (Figure 4A). RG-1 reactivity was
greatlydiminishedalbeitnotcompletelyabolishedwhenHaCaTcells
were infected in the presence of NIM811 (Figure 4A), whereas
Figure 1. CyP facilitate HPV infection. 293TT (A), HaCaT (B), or HeLa cells (B) were infected with HPV16 (A,B,C) or HPV18 pseudovirus (B) in
presence of indicated inhibitors and infection was scored at 72 hpi. (D) Effect of drugs on cell growth was determined by the MTT assay. We did not
notice significant increase in cell death. CsA: cyclosporine A; VIVIT: cell permeable 11R-VIVIT; Nfdp: nifedipin; Vpml: verapamil. Representative graphs
are based on three replicates each with standard deviation indicated.
doi:10.1371/journal.ppat.1000524.g001
CyP and HPV Infection
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decreased RG-1signalalbeit not as pronounced (data not shown). We
quantified the RG-1- and K75-specific signals using software
provided by Zeiss and found statistically significant reductions of
over 70% and 59% of relative RG-1 signal strength in presence of
NIM811andCsA,respectively(p,0.01)(Figure4B).Takentogether,
these data strongly suggest that CyPB activity is required for exposure
of the RG-1 epitope on the viral capsid and lend support for a
function of cell surface CyPB in HPV16 infection.
Recently, it has been shown that the presence of RG-1 antibody
during infection of HaCaT cells with HPV16 pseudovirions
prevents infection and virus internalization and relocates viral
particles from the cell surface to ECM [24]. We took advantage of
this observation to strengthen our findings. We reasoned that,
irrespective of presence of RG-1, viral particles should still be
internalized and display a stabilized capsid phenotypein presenceof
NIM811, if the RG-1 epitope is indeed not accessible to antibody
binding after drug treatment. To test this, HPV16 pseudovirus was
bound to HaCaT cells for 2 h at 4uC in the presence or absence of
this drug. After washout of unbound virus, cells were incubated
overnight in presence of NIM811 and RG-1. Confirming previous
findings [24], RG-1 treatment alone induced deposition of the
majority of viral particles to ECM in the absence of NIM811, as
evidenced by colocalization of capsid-specific H16.56E signal with
the ECM marker Laminin 5 (Figure 5A). We also confirmed the
neutralizing capacity of RG-1 using 293TT cells (Figure 5C) to
ascertain that this antibody is functional in our hands. Inhibition of
HPV16 pseudovirus infection by this antibody using HaCaT cells
was previously demonstrated by others [24,37]. However, the
presence of RG-1 antibody in addition to drugs did not prevent
internalization of viral capsids, as evidenced by a stabilized capsid
phenotype (Figure 5B) and did not result in increased deposition of
viral particles on ECM (not shown). It should be noted that RG-1
treatment in the absence of NIM811 displayed a weak but
reproducible stabilized capsid phenotype (Figure 5B) suggesting
that not all particles are displaced from the cell surface and are
instead internalized in a noninfectious manner. These data further
support our notion that CyPB action on the cell surface is required
for the conformational change resulting in exposure of the RG-1
epitope, which is a prerequisite for infectious internalization.
A putative binding site for CyP at the L2 N-terminus
Not much information is available regarding CyPB substrate
binding sites. However, CyPA binding to the HIV capsid protein
has been mapped to 85-PXXXGPXXP-93, which is located
between Helix 4 and 5 [7]. We found similar sequence elements at
the N-terminus of L2 conserved among many but not all members
of the Papillomaviridae family (Figure 6A). We exchanged glycine
and proline residues of L2 at positions 99 and 100 within the
putative CyP binding site for alanine to test their importance for
Figure 2. Knock down of CyP inhibits HPV16 infection. 293TT (A,B) or HaCaT (C,D) cells were transfected with indicated siRNA and infected
with HPV16 pseudovirus 48h after transfection. Infection was scored at 72 hpi. Representative graphs based on six replicates are shown (A,C).
Knockdown of CyPA and CyPB was confirmed by Western blot prior to infection (B,D). Numbers indicate percent levels of protein after correcting for
input (D). *: p,0.05; **: p,0.01.
doi:10.1371/journal.ppat.1000524.g002
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defective for infection due to loss of CyP binding or does not
require active CyP for exposure of the L2 N-terminus due to
higher flexibility in this L2 region induced by amino acid
exchanges. We found that 16L2-G99A-P100A (16L2-GP-N) is
incorporated into particles similar to wt L2 (not shown). Mutant
pseudovirus retains full infectivity in 293TT (Figure 6B) and
HaCaT cells (data not shown), which is consistently and
statistically significantly increased compared to wt (p,0.01).
When we bound 16L2-GP-N mutant pseudovirus to HaCaT cells
and surface-stained with RG-1 and K75 after a 4 h chase at 37uC,
we observed similar reactivity of RG-1 with cell-bound pseudovir-
ions in absence or presence of NIM811 (Figure 6C). Quantitative
analysis of signal strength confirmed that reactivity of RG-1 with
mutant pseudovirus is not significantly reduced by this drug
(Figure 6D) in contrast to wt pseudovirus (Figure 4). These data
suggested that 16L2-GP-N mutant pseudovirus does not require
CyP activity for exposure of the RG-1 epitope. Nevertheless,
infection was still sensitive to CsA (Figure 7A) and siRNA knock
down of CyP (Figure 7B). However, unlike wt pseudovirus mutant
pseudovirus did not produce the stabilized capsid phenotype after
treatment with drugs (Figure 7C) or siRNA knock down of CyP
(not shown), although H16.56E was still able to detect mutant viral
particles on the cell surface and on ECM (data not shown). Taken
together, these data indicate not only that 16L2-GP-N mutant
pseudovirus bypasses the requirement for cell surface CyPB but
also that HPV16 infection requires CyP at a second, possibly
intracellular, stage of entry and transport. Furthermore, they
strongly support our previous notion that, in presence of CyP
inhibitors, wt virus is shunted into a noninfectious entry pathway.
To determine whether the requirement for CyP is a conserved
feature among papillomaviruses we tested a number of low and
Figure 3. Inhibition of CyP leads to noninfectious HPV16 internalization. (A) HaCaT cells were infected with HPV16 pseudovirus in the
absence or presence of NIM811. At 18 hpi cells were fixed and stained using conformation-dependent NmAb H16.56E or linear epitope-specific
nonneutralizing 33L1-7. Cells were also stained for actin and DNA using AF
488–labeled phalloidin (green) and Dapi (blue), respectively. Images were
taken with a Leica DBMI6000 at 406 magnification. (B) HaCaT cells were transfected with indicated siRNA. At 48 hpTx, cells were harvested and
reseeded for infection with HPV16 pseudovirions. At 18 hpi cells were fixed and stained using H16.56E (red) and CyPA or CyPB (green). Images were
taken with a confocal Zeiss LSM 510 microscope at 636magnification.
doi:10.1371/journal.ppat.1000524.g003
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that HPV6, HPV45 and HPV58 were inhibited by CsA similar to
HPV16 and HPV18, whereas BPV1, HPV5, HPV31, and HPV52
were relatively resistant to CsA (Table 1). These data suggest that
different papillomavirus types have different requirements for CyP,
which may be reflective of the entry strategies these viruses evolved.
Discussion
Here, we report that CyP facilitate infection of the oncogenic
HPV16 and 18 among other HPV types. Focusing on HPV16 and
using specific drugs, siRNA knock down and mutant pseudovirus
we provide evidence that CyP are required at two different stages
following primary attachment to host cells. In addition, siRNA
knock down data point to the involvement of two members of the
CyP family in the infection process: CyPA and CyPB. Combined
knock down using siCyP[broad] affected infection more severely
than individual knock downs suggesting they may facilitate
different steps of HPV16 infection. Our data indicate that CyPB
is functioning on the cell surface. However, we were not yet able to
identify the step requiring CyPA. Also, at the moment we cannot
completely rule out the involvement of additional CyP family
Figure 4. CyP facilitate exposure of the RG-1 epitope after cell attachment. HPV16 pseudovirus was bound to HaCaT cells for 2 h at 4uC and
chased for 4 h at 37uC in presence or absence of NIM811. (A) Cells were subsequently stained with L2-specific RG-1 and L1-specific K75 antibody. All
images were taken using the same settings. (B) RG-1– and K75–specific signal strength of randomly selected cells (n.15 for each group) was
measured. RG-1 reactivity normalized to K75 signal strength is plotted after subtraction of background signal. The graph shows quantifications from
one experiment. However, the experiment was repeated three times with similar outcomes.
doi:10.1371/journal.ppat.1000524.g004
CyP and HPV Infection
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affected by siCyP[broad].
We provide evidence that cell surface CyPB is essential for
triggering events that lead to infectious internalization of viral
particles probably by catalyzing conformational changes of viral
capsid proteins. It is well established that both HPV16 capsid
proteins undergo conformational changes on the cell surface prior
to internalization. Conformational changes induced in L1 are not
well defined but seem to involve the BC loop [23]. Conformational
changes induced in L2 protein result in exposure of some forty N-
terminal amino acids, which allows furin convertase-mediated
cleavage of L2 and binding of the L2-specific NmAb RG-1
[24,25,38]. CyP inhibition greatly reduced exposure of the RG-1
epitope following cell attachment as measured directly by IF and
indirectly by determining the fate of cell bound pseudovirus in the
presence of CyP inhibitors and RG-1. This strongly indicates that
CyP activity is required to make the RG-1 epitope accessible to
antibody binding. However, the block was not complete and
residual reactivity with RG-1 was observed in presence of
inhibitors, which could possibly be attributed to the presence of
activated particles in the pseudovirus preparation [18,28] and/or
to the baseline spontaneous conformational change in absence of
CyP activity due to receptor engagement. Nevertheless, the
reduction in RG-1 reactivity by CyP-specific drugs was found to
be correlated with reduction of infectivity by drugs.
We also provide evidence that L2 protein may be the substrate
for CyP. First, we were able to bypass the requirement for cell
surface CyP by introducing amino acid changes in a putative CyP
Figure 5. Effect of RG-1 on particle internalization. (A) HPV16 pseudovirus was added to HaCaT grown on coverslips and incubated for 18 h at
37uC in the presence or absence of RG-1 (1:10 dilution of cell culture supernatant). Samples were stained for viral particles and ECM using H16.56E
and rabbit polyclonal antiserum specific for laminin 5, respectively. Note the accumulation of viral particles on ECM in presence of RG-1. As fixation
prior to addition of secondary antibody destroys reactivity with RG-1 [24, and our own observations], the signal picked up by mouse-specific
secondary antibody is solely attributable to H16.56E. (B) HaCaT cells were grown and infected as above with the addition of NIM811 during the
incubation where indicated. Samples were stained with H16.56E. Note that the presence of RG-1 did not affect the stabilized capsid phenotype and
viral internalization irrespective of NIM811 treatment. Images were taken with a Zeiss LSM at 636magnification focusing on ECM (A) and cells (B),
respectively. Actin staining with labeled phalloidin is shown in blue. (C) Neutralization of HPV16 by RG-1 at indicated dilutions was measured at
72 hpi of 293TT cells (n=5).
doi:10.1371/journal.ppat.1000524.g005
CyP and HPV Infection
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Mutant pseudovirus did not require CyP activity for exposure of
L2 as demonstrated by IF. However, at this point we cannot
completely rule out that CyP functions rather indirectly by (i)
modifying cell surface receptors, since CyP have been shown to
isomerize prolyl peptide bonds of cell surface markers, thus
modifying their biological function [40,41], and by (ii) regulating
cell trafficking and cell surface expression of proteins [42].
However, this is rather unlikely since BPV1, which uses the same
route of internalization as HPV16 [43,44], is not blocked by CyP
inhibitors. Second, specific blockage of CyPB induced noninfec-
tious internalization with the hallmark of a stabilized capsid
phenotype. In this respect CyPB inhibition is similar to post-
attachment treatment with the BC loop-specific antibody H33.J3,
heparinase, or the HS binding drug DSTP-27, which also induce
noninfectious internalization and stabilization of viral capsids [18].
It was suggested that these treatments all block secondary receptor
interactions, which seems to require an exposed L2 N-terminus
[18]. It is unlikely that L1 rather than L2 protein is the substrate of
CyP. This is based on our unpublished observations that CsA,
NIM811 or CyP-specific siRNAs do not block L1 conformational
changes occurring on the cell surface.
Interestingly, mutant 16L2-GP-N pseudovirus remained sensi-
tive to CyP inhibitory drugs and siRNA knock down. However,
bypassing the need for cell surface CyPB using mutant pseudovirus
yielded an inhibition phenotype distinct from wt particles. We no
longer observed capsid stabilization. This suggests that CyP
activity is required at a subsequent step during internalization
and/or intracellular transport. So far, we were not able to identify
the exact step(s) that require CyP activity and therefore cannot
predict which specific CyP family member may be involved.
However, a second putative CyP binding site is located near the C-
terminus of L2 (409-PLVSGPDIP-417). This sequence is close to
a region that has been shown to mediate interaction of L2 with L1
capsomeres in HPV11 [45]. It is therefore tempting to speculate
that endocytic CyP mediates segregation of L2 from L1. As the C-
terminal section of L2 is required for membrane destabilization
and passage of membranes [30] as well as for interaction with
dynein [46], this could free the C-terminus allowing association
and penetration of surrounding membranes and consequently the
L2/DNA complex to egress from endosomes and retrograde
transport towards the nucleus. CyPB encodes a signal peptide and
is therefore found in the luminal compartment of intracellular
membranes making it a likely candidate. However, CyPA is also
secreted into the extracellular space, even though it lacks a signal
peptide, suggesting it finds its way into the luminal compartment
of at least the secretory pathway.
Host cell CyP do not facilitate infection of all papillomaviruses.
Support for this notion came from our finding that HPV5,
HPV31, HPV52, and BPV1 are rather resistant to CyP-specific
Figure 6. L2 protein is the likely target of CyPB. (A) Sequence alignment of selected PV L2 proteins with CyPA binding site of HIV capsid
protein. (B) 293TT cells were infected with similar amounts of HPV16 wt and 16L2-GP-N mutant pseudovirus and scored at 72 hpi. The difference in
infectivity is statistically significant (p,0.01; n=5) based on testing two independent pseudovirus preparations. (C) 16L2-GP-N mutant pseudovirus
was bound to HaCaT cells in presence or absence of NIM811 for 4 h at 37uC and subsequently stained with RG-1 and K75. All images were taken with
the same settings. (D) Quantification of RG-1 and K75 signal strength using randomly selected cells (n.15).
doi:10.1371/journal.ppat.1000524.g006
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strategies. For example, HPV31 is internalized via caveolae-
dependent endocytosis [31,47] whereas HPV16 uses a caveolae-
and clathrin-independent pathway [32]. BPV1 L2 does not harbor
putative CyP binding sites and replacing key proline residues by
more flexible amino acids may make a catalytic activity
dispensable for L2 exposure, as we have shown with HPV16L2-
GP-N. The entry pathways of HPV5 and HPV52 have not been
investigated yet. However, the L2 protein of both HPV types has a
putative N-terminal CyP binding site.
Attachment-induced conformational changes are a common
theme in virus infection. They are usually triggered by interaction
with specific receptors, which allows interaction with secondary
receptors or, more often, trigger cell fusion events. Although
chaperones present in endocytic vesicles or the endoplasmic
reticulum have been shown to facilitate virus uncoating and
translocation across membranes [48,49], this is the first report to
implicate chaperones in mediating conformational changes of
capsid proteins on the surface of target cells.
With this report we are adding another virus family to the list of
viruses dependent on CyP activity for completion of their life cycle.
Despite 15 years of study, the role of CyPA in HIV-1 infection is
not yet fully defined (for review see [7,50]). Similarly, its
involvement in MCMV infection of neural progenitor cells has
not been characterized in molecular detail [12], whereas it was
convincingly demonstrated for HCV that ER-resident CyPB
enhances the RNA binding activity of the NS5B RNA polymerase
and consequently genome amplification [11]. With the identifica-
tion of CyPB as modifier of oncogenic HPV capsid protein
conformation, which activates the virus for entry via an infectious
pathway, for the first time we have characterized its role at the
molecular level during cell surface events of viral infections. This
should allow characterizing the complex events preceding
internalization in more detail and adds a putative drug target for
prevention of HPV-induced diseases, especially since CsA has
been approved for and is already being used in clinical settings.
Materials and Methods
Cell lines, plasmids, antibodies, and pseudovirions
293TT cells and expression plasmids for codon-optimized
structural genes coding for HPV5, HPV6, HPV18, HPV31,
HPV45, HPV52, HPV58 as well as BPV1 were kindly provided by
John Schiller and Chris Buck, Bethesda [27,51]. Codon-optimized
HPV16 L1 and L2 expression plasmids were a kind gift from Martin
Mu ¨ller, Heidelberg [52]. HPV16L1-specific rabbit polyclonal
antisera K75, mouse monoclonal antibody H16.56E and 33L1-7
have been described previously [34,35]. Anti-CyPA polyconal rabbit
antibody was obtained from Dharmacon (cat #: 07-313). CyPB
polyclonal rabbit antibody was purchased from Affinity BioReagents
Inc (Golden, Colorado; cat #: PA1-027). However, we noticed that
only lot number 328-120 and prior lots were reactive in IF. All
subsequent lots tested were not reactive in IF analyses. Laminin 5
Figure 7. Mutant pseudovirus infection is impaired by CyP inhibitors. (A) Sensitivity of 16L2-GP-N mutant pseudovirus to CsA was
determined by infection of 293TT cells. (B) 293TT cells were transfected with indicated siRNA and infected with mutant pseudovirus at 48 hpTx and
scored at 72 hpi. *: p,0.01. (C) HaCaT cells grown on coverslips were infected with HPV16 wt or 16L2-GP-N mutant pseudovirus. At 18 hpi cells were
stained with H16.56E (red) and labeled phalloidin (blue).
doi:10.1371/journal.ppat.1000524.g007
Table 1. Sensitivity of PV types to CsA
PV type 2 mMC s A 1 0mMC s A
6 45.3 (7.4) 11.9 (2.1)
45 70.4 (1.9) 20.9 (1.1)
58 63.8 (10.4) 20.7 (6.8)
5 93.7 (0.9) 83.3 (2.7)
31 93.4 (2.7) 51.7 (5.6)
52 80.4 (9.0) 73.5 (7.0)
BPV1 81.0 (7.8) 68.4 (17.6)
Values represent percent infection with standard deviations in parentheses.
Values are based on five replicates with the exception of HPV5 and HPV52
(three replicates).
doi:10.1371/journal.ppat.1000524.t001
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488-
labeled GFP-specific rabbit polyclonal antibody was obtained from
Invitrogen. Mouse monoclonal L2-specific RG-1 antibody was kindly
provided by Richard Roden, John Hopkins University, Baltimore.
AlexaFluor (AF)–labeled secondary antibodies and phalloidin were
purchased from Invitrogen. Pseudovirions were generated and
purified using Optiprep gradient centrifugation following published
procedures [27]. Pseudovirus yield was determined by green
fluorescent protein (GFP)–specific quantitative real time polymerase
chain reaction (qRT–PCR).
Inhibitors and reagents
Cyclosporin A was obtained from Toronto Research Chemicals
(cat #: C988900). NIM811 was a kind gift from Novartis.
Verapamil (cat #: 676777), Nifedipine (cat #: 481981), 11R-
VIVIT (cat #: 480401) and INCA-6 (cat #: 480403) were obtained
from Calbiochem. FK 506 (cat #: F1030) was purchased from A.G.
Scientific (San Diego). The cell viability and proliferation assay
‘CellTiter96 Aqueous One Solution’ was purchased from Promega
(Madison, WI). This assay measures the quantity of formazan
product, which is directly proportional to the number of living cells.
Infection assay
293TTcellswereseededadaybeforeandallowedtoattach.Next
day, drugs were serially diluted in complete DMEM in 24 well-
plates and adequate amounts of pseudoviruses were added to
achieve infection levels of 10 to 30%. Infectivity was scored by
counting GFP expressing cells at 72 hpi using flow cytometry.
Similar protocol was followed for infection assay using HaCaT and
HeLa cells except that cells were fixed with 2% paraformaldehyde,
permeabilized with 0.2% Triton X-100 inphosphate buffered saline
(PBS), stained with AF
488-labeled GFP-specific antibody and
counted using a Leica DMBI 6000 fluorescence microscope. Unless
otherwise stated standard deviation was based on at least five
replicates from at least two independent experiments.
RNA interference
RNA interference was carried out using synthetic siRNA
duplexes with symmetric 39-deoxythymidine overhangs. siRNA
duplexes si-CyPA, 59-AAGCATA CGGGTCCTGGCATC-39;s i -
CyPB, 59-AAGGTGGAGAGCACCAAGACA-39; and si-Cy-
P(broad), 59-AAGCATGTGGTGTTTGGCAAA-39), which have
been described and validated before [11], were purchased from
Integrated DNA Technologies Inc. Non-specific siRNA, si-NS, 59-
AAGTCCGTGCCGTCAGTTCTCAGAA-39 was obtained from
Invitrogen. Cells were transfected with 3 mg of siRNA duplexes in
serum-free medium using MATra reagent (IBA biotagnology,
Goettingen; cat. #: 7-2001-100) according to manufacturer’s
protocol. Typical siRNA transfection efficiency was found to be
70% for HaCaT and 95% for 293TT cells as monitored by
fluorescein-labeled control siRNA duplex. CyP knockdown was
confirmed 48 h post siRNA transfection (hpTx) by Western blot.
Infection and immunofluroscence assay after siRNA
knockdown of CyP
HaCaT and 293TT cells were transfected with siRNA as
mentioned above. 48 hpTx, HaCaT were harvested with trypsin
and reseeded onto cover slip for immunofluorescence study. Few
hours later, when cells had attached, they were infected. At 18 hpi
samples were fixed with 4% paraformaldehyde and stained.
Alternatively, cells were incubated for 72 h and subsequently
stained for GFP as described above to score infection [18]. For
infection assay using 293TT, cells were harvested, reseeded into 96
well plates and allowed to attach. Few hours later, they were
infected and scored at 72 hpi by counting GFP positive cells.
Immunofluorescence in presence of CyP inhibitor
HaCaT cells were grown on cover slips till ,50% confluency and
infected with HPV16 pseudovirus in presence of NIM811,
antibody, or DMSO. At the indicated times post infection, cells
were washed with PBS and fixed with 4% paraformaldehyde for
15 min at room temperature, washed, permeabilized with 0.2%
Triton X-100 in PBS for 2 min, washed, and blocked with 5% goat
seruminPBSfor30 min,followedbya1 hincubationwithprimary
antibodies at 37uC. After extensive washing, cells were incubated
with AlexaFluor-tagged secondary antibodies and fluorescently
labeled phalloidin for 1 h. After extensive washing with PBS, cells
were mounted in ‘Gold Antifade’ containing Dapi (Invitrogen).
Images were captured by confocal microscopy (Zeiss 510 Laser
Scanning Confocal Microscope operated by LaserSharp2000
software) or by standard fluorescence microscopy (Leica DMBI
6000 microscope). Within individual experiments the same
microscope settings and exposure times were used. For quantifica-
tion of fluorescent signal intensity, the LSM server software
provided with the confocal microscope was used. Signal strength
was acquired from randomly selected single cells (n.15 for each
group). The average region of interest was not significantly different
among all groups. Background was determined using mock infected
cells and subtracted prior to calculations.
RG-1 staining was performed as described [24]. In brief,
infected HaCaT cells were shifted to 4uC and incubated with RG-
1 and K75 for 1 h in presence of 2% normal goat serum. After
extensive washing and incubation with fluorescently labeled
secondary antisera, cells were fixed for 20 min in 2% paraformal-
dehyde. After washing, cells were incubated for 5 min with
phalloidin-AF
647 conjugate and mounted.
Accession numbers for genes and proteins mentioned in
the text
CyPA: NM_021130; CyPB: NM_000942; codon optimized
HPV16 L1: AJ313179; codon optimized HPV16 L2: AJ313180
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